DelveInsight’s, “Metastatic Breast Cancer Pipeline Insight” report provides comprehensive insights about 100+ companies and ...

Recent advances in immunotherapy have revolutionized the treatment of breast and gynecological cancers, and current ...

If you have metastatic breast cancer, you may need help from loved ones and your medical team along the way. Here’s how to ...

We think Roche's drug portfolio and industry-leading diagnostics conspire to create maintainable competitive advantages. As the market leader in both biotech and diagnostics, this Swiss healthcare ...

A far shorter, simpler, and less toxic treatment protocol for patients with triple-negative breast cancer produced outcomes ...

Swiss pharma giant Roche Holding AG RHHBY posted better-than-expected 2024 results and provided an encouraging outlook for ...

Atezolizumab (Tecentriq) plus chemotherapy after surgery did not improve survival in high-risk triple-negative breast cancer, according to a global phase 3 trial.

T-DM1 sustained the improvement in invasive disease-free survival over trastuzumab in HER2-positive early breast cancer.

Professor Meghan Morrissey earns an innovation award to program immune cells to attack cancer tumors. #immunotherapy ...

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

Several new treatment options for patients with breast cancer have emerged over the last few years, including more oral ...

Adjuvant chest wall irradiation should be omitted in most patients meeting the eligibility criteria for SUPREMO,” said Ian Kunkler, MB BChir.